Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood ...

Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024 ...

Bristol Myers Squibb (NYSE: BMY) today announced that new clinical ... “Building on momentum from the recent U.S. Food and Drug Administration’s approval of COBENFY for the treatment ...

Evotec announced in May of 2022 that the Company has further extended and expanded its partnership with Bristol Myers Squibb for another 8 years as the initial collaboration proved to be highly ...

UMB's lawsuit claimed Bristol Myers Squibb slow-rolled FDA applications ... three of Celgene’s drugs won approval from the Food and Drug Administration by a certain date. That approval didn ...

Reports of drug-related supply-chain issues were 40 percent less likely to result in drug shortages in Canada versus the United States, according to a new study.

Grogan, who maintains that the GOP should not extend additional ACA premium subsidies passed under the Biden administration ... s Matthew Herper picked Bristol Myers Squibb CEO Chris Boerner ...

Such is the case with newly approved Bristol-Myers Squibb drug Cobenfy ... and last month it was approved for use by the U.S. Food and Drug Administration, making it the first new antipsychotic ...

On Sept. 26, for the first time in nearly 30 years, the U.S. Food and Drug Administration approved a new oral drug, Cobenfy, developed by Bristol Myers Squibb, to treat schizophrenia. Schizophrenia is ...